Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
21.80
+0.79 (3.76%)
At close: Feb 6, 2026, 4:00 PM EST
21.54
-0.26 (-1.19%)
After-hours: Feb 6, 2026, 7:13 PM EST
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover Zenas BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $38.38, which forecasts a 76.06% increase in the stock price over the next year. The lowest target is $19 and the highest is $55.
Price Target: $38.38 (+76.06%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 6, 2026.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $37 → $19 | Buy → Hold | Downgrades | $37 → $19 | -12.84% | Jan 6, 2026 |
| Wedbush | Wedbush | Buy Reiterates $45 | Buy | Reiterates | $45 | +106.42% | Dec 22, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +152.29% | Nov 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $34 → $37 | Buy | Maintains | $34 → $37 | +69.72% | Nov 13, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $27 → $46 | Strong Buy | Maintains | $27 → $46 | +111.01% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
29.75M
from 5.00M
Increased by 495.00%
Revenue Next Year
n/a
from 29.75M
EPS This Year
-4.15
from -11.89
EPS Next Year
-4.65
from -4.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 89.3M | n/a | ||||
| Avg | 29.8M | n/a | ||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,685.0% | - | ||||
| Avg | 495.0% | - | ||||
| Low | 96.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.73 | -3.64 | ||||
| Avg | -4.15 | -4.65 | ||||
| Low | -5.23 | -5.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.